期刊文献+

醋酸亮丙瑞林的临床应用和制剂研究进展 被引量:23

Progress of the clinical application and the drug delivery system of leuprorelin acetate
下载PDF
导出
摘要 醋酸亮丙瑞林是视丘下部所产生的黄体生成激素释放激素(LHRH)的高活性衍生物,为合成的两端封闭的水溶性九肽。它可以刺激垂体分泌促性腺激素,诱发生殖器官生成类固醇,长期大量使用会使LHRH受体脱敏,抑制促性腺激素的分泌以及睾丸或卵巢甾类的生成,临床上用来治疗或缓解多种性激素依赖性疾病如前列腺癌、子宫内膜异位症、子宫肌瘤、中枢性性早熟等。但是醋酸亮丙瑞林不易透过生物膜,在胃肠道中不稳定,易被消化酶降解,口服、鼻腔、直肠、阴道途径给药生物利用度极低,所以目前人们针对醋酸亮丙瑞林的非胃肠道给药途径的制剂进行了广泛的研究,有些已经成功开发为上市药品。本文主要就醋酸亮丙瑞林的临床应用及其制剂的研究情况进行综述。 Leuprorelin acetate, an analogue of the luteinizing hormone-releasing hormone (LHRH) with high bioactivities, is a synthesized nona-pcptide which can stimulate the pituitary releasing gonadotropin and induce reproductive organs producing steroids. Long-term use of lueprolide acetate can bring on LHRH-receptor desensitization and decrease the gonadal hormone level. Thus, it is used to cure or relief the symptoms of prostate cancer, endometriosis and so on. Because of poor biomembrane permeation ability, the parenteral delivery syestem of this drug is concerned and has been studied widely. The current research of the clinical application and the drug delivery system of leuprolide acetate is reviewed.
作者 刘婧 涂家生
出处 《药学与临床研究》 2009年第4期309-315,共7页 Pharmaceutical and Clinical Research
基金 国家科技支撑计划(2008BA155B03)
关键词 醋酸亮丙瑞林 缓释 微球 原位成形 前列腺癌 Leuprolide acetate Sustained release Microspheres In situ forming Prostate cancer
  • 相关文献

参考文献16

二级参考文献77

  • 1李真,林桂兰.GNRH-a治疗子宫内膜异位症的副作用及其防治进展[J].中国优生与遗传杂志,2004,12(S1):155-156. 被引量:4
  • 2李琴,平其能,王秋娟,郭建新.前列地尔脂质体的制备及刺激性考察[J].中国新药与临床杂志,2004,23(7):423-426. 被引量:8
  • 3孔良,叶敏,陈建华.经尿道电汽化术治疗中晚期前列腺癌[J].现代泌尿外科杂志,2001,6(1):31-32. 被引量:15
  • 4[1]Hall SC,Tan MM,Leonard JJ,et al.Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide[J].J Peptide Res,1999,53:433-441. 被引量:1
  • 5[2]Hoffman HN,Ghanbari DJ.Stabilization of the N-terminal Residues of LHRH agonists and the effect on pharmacokinetics[J].J Med Chera,1992,35:3890-3894. 被引量:1
  • 6[3]Zheng Y,Fu LM,Qiu Y,et al.Enzymatic degradation of leuprolide in rat intestinal mucosal homogenates[J].Pharm Develop Technol,1999,4:539-544. 被引量:1
  • 7[4]Adjei P,Sundberg D,Miller J,et al.Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans[J].Pharm Res,1992,9:244-249. 被引量:1
  • 8Elders MJ, Scott CR, Frindik JP,et al. Clinical workup for precocious puberty[J]. Lancet, 1997,350 (9076) : 457~458. 被引量:1
  • 9Palmert MR,Malin FIV, Boepple PA. Unsustained or slowly progressive puberty in young girls: Initial presentation end long-term follow-up of 20 untreated patients[J]. J Clin Endoerinol Metab,1999, 84: 415~423. 被引量:1
  • 10Boulgourdjian E. Bone age and discontinuation of medroxyprogesteronne acetate therapy in girls with precocious puberty: effection final height[J]. Acta Paediatr, 1994, 83(6):623. 被引量:1

共引文献72

同被引文献177

引证文献23

二级引证文献190

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部